The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
BB Biotech AG (BION:SW) Annual Income Statement ()
BION:SW Quarterly Financials ()
Frequently Asked Questions About BB Biotech AG (BION:SW) Stock
BB Biotech AG's (BION:SW) last reported annual revenue was N/A.
BB Biotech AG's (BION:SW) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
BB Biotech AG's(BION:SW) is not profitable as of its last reported annual financials.
The net profit margin for BB Biotech AG's(BION:SW) from its laster reported year is N/A
The return on equity (ROE) for BB Biotech AG's(BION:SW) from its last reported annual financials is : 12.96%
The return on assets (ROA) for BB Biotech AG's(BION:SW) from its last reported annual financials is : 5.48%
The return on invested capital (ROIC) for BB Biotech AG's(BION:SW) from its last reported annual financials is : -8.25%
The Debt to Equity ratio for BB Biotech AG's(BION:SW) from its last reported annual financials is : 0.00%
The dividend yield for BB Biotech AG's(BION:SW) from its laster reported year is 4.99%
BB Biotech AG's(BION:SW) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BION:SW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
